Andrea Pires Souto Damin

Dr. Andrea Pires Souto Damin

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2018 in Aesthetic Plastic Surgery
Verified
Journal Article
Closed access
PDF file
JBJorge Villanova Biazus
Jorge Villanova Biazus
CSCamile Cesa Stumpf
Camile Cesa Stumpf
MMMarcia Portela Melo
Marcia Portela Melo
AZAngela Erguy Zucatto
Angela Erguy Zucatto
RCRodrigo Cericatto
Rodrigo Cericatto
ADAndrea Pires Souto Damin
Andrea Pires Souto Damin

9 November 2020 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
ADAndrea Pires Souto Damin
Andrea Pires Souto Damin
MZMaira Zancan
Maira Zancan
MMMarcia P. Melo
Marcia P. Melo
JBJorge V. Biazus
Jorge V. Biazus

CBCamila Zanella Zanella Battistello
Camila Zanella Zanella Battistello
EREduardo Remor
Eduardo Remor
CCCosta Costa
Costa Costa
MOMônica Echeverria de Oliveira
Mônica Echeverria de Oliveira
ADAndrea Pires Souto Damin
Andrea Pires Souto Damin
Breast cancer is a condition characterized by the uncontrolled growth of breast cancer cells. The treatment for the disease, such as surgery, chemotherapy, radiotherapy, and systemic therapy, can significantly impact patients’ body image and overall quality of life. This study aimed to evaluate body image perceptions and cancer-related quality of life in women who underwent surgical treatment for breast cancer at a reference hospital in southern Brazil. One hundred six women with breast cancer, aged 21 to 93 years (M = 55.3; SD = 12.9), participated in this cross-sectional study. They responded to the Body Image and Relationships Scale (BIRS), Functional Assessment of Cancer Therapy for Breast Cancer scale (FACT-B), and a questionnaire on clinical and sociodemographic variables. Multiple linear regression analyses revealed that general perceived body image, as measured by BIRS, was significantly predicted by younger age and chemotherapy (F(2, 99) = 7.376, p = 0.003). These predictors accounted for 11.2% of the variance in BIRS (adjusted R2 = 0.112). Hierarchical multiple regression analysis indicated that cancer-related quality of life was significantly predicted by younger age, use of psychiatric medication, and body image domains, including strength and health, social barriers, and appearance and sexuality. The complete model, encompassing all predictors, was significant (F(5, 96) = 15.970, p < 0.001) and explained 42.6% of the variance in FACT-B (adjusted R2 = 0.426). Clinicians should be aware that younger patients who have undergone chemotherapy for breast cancer may experience changes in body image perception following surgery. Contributing factors such as younger age, use of psychiatric medications, and negative postoperative body image may be associated with a diminished quality of life related to cancer.

22 November 2022 in BMC Cancer
Verified
Journal Article
Open access
PDF file
RFRuffo Frritas-Junior
Ruffo Frritas-Junior
VOVilmar Marques Oliveira
Vilmar Marques Oliveira
AFAntonio Luiz Frasson
Antonio Luiz Frasson
FCFrancisco Pimentel Cavalcante
Francisco Pimentel Cavalcante
FMFabio Postiglione Mansani
Fabio Postiglione Mansani
VBVinicius Milani Budel
Vinicius Milani Budel
Triple-negative breast cancer (TNBC) is a heterogenous subtype involving different patterns of behavior and clinical course, demanding a complex, individualized sequence of treatment. The knowledge and attitudes of the affiliated members of the Brazilian Society of Mastology regarding TNBC were evaluated and a consensus regarding management and treatment was reached. Affiliates completed a survey involving 44 objective questions. In addition, a specialist meeting was held with 27 experts and 3 ad hoc consultants. The panelists completed the survey before and after brainstorming. Answers achieving 70% of agreement were considered consensual. The chi-square test was used to compare answers between panelists and affiliates and the Kappa coefficient to calculate agreement. Consensus among the panelists increased from 26 (59.1%) to 32 questions (72.7%) following brainstorming (p = 0.17), including 7/10 questions on systemic treatment. Among the affiliates, consensus was achieved for 24 questions (54.5%), resulting in moderate agreement (κ = 0.445). Neoadjuvant chemotherapy should be indicated for almost all cases (except cT1a-b N0) and should include platinum agents. When indicated, immunotherapy is part of the standard of care. The panel reaffirmed the concept of no ink on tumor as indicative of adequate margins and the possibility of sentinel lymph node biopsy for cN1 patients who become cN0 following neoadjuvant therapy. Controversies remain on combining immunotherapy with capecitabine/olaparib in pertinent cases. Expert consensus was achieved for > 70% of the questions, with moderate agreement between panelists and affiliates. Educational interventions on systemic breast cancer treatment affected decision-making in 60% of the questions.

1 February 2021 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
RNRosana Pellin De Nardi
Rosana Pellin De Nardi
DUDiego Uchoa
Diego Uchoa
GRGabriela Remonatto
Gabriela Remonatto
JBJorge Villanova Biazus
Jorge Villanova Biazus
ADAndrea Pires Souto Damin
Andrea Pires Souto Damin
Currently, there is an ongoing debate whether progesterone receptor positive and estrogen receptor negative breast carcinomas represent a true distinct subtype of tumor or a mere immunohistochemical artifact. In this study, we conducted an immunohistochemistry panel with the antibodies TFF1, EGFR, and CK5 to reclassify this phenotype in a luminal or basal-like subtype. Tumors estrogen receptor -/progesterone receptor +, Her-2 - from a large population of breast cancer patients were selected to be studied. Immunohistochemistry with the antibodies TFF1, EGFR, and CK5 was performed. Tumors showing positivity for TFF1, regardless of EGFR and CK5 results, were classified as luminal-like carcinomas. Those lesions that were negative for TFF1, but were positive for EGFR and/or CK5, were classified as basal-like triple-negative carcinomas. When the three markers were negative, tumors were classified as undetermined. Clinical pathologic characteristics of patients and tumor recurrence were evaluated. Out of 1188 breast carcinomas investigated, 30 cases (2.5%) presented the estrogen receptor -/progesterone receptor +/HER2- phenotype. Of them, 27 tumors (90%) were classified as basal-like triple-negative carcinomas, one as luminal-like (3.3%), and two as undetermined tumors (6.7%). The mean follow-up for the study group was 27.7 (2.7 to 50) months. Out of the 26 patients, 6 had cancer recurrence: 2 local and 4 systemic recurrences. The average time for recurrence was 17 (8 to 38) months. Estrogen receptor -/progesterone receptor +/tumors exhibit aggressive behavior, similar to triple-negative tumors. An appropriate categorization of these tumors should be made to improve their therapeutic management.